nc medicaid glp-1 coverage for obesity treatment in 13 US states' programs Expected NC budget won’t restore

Impact of initiating a GLP1 agonist and/or SGLT2 inhibitor therapy on de-escalation and discontinuation of insulin and diabetes control when managed by an Interprofessional Collaborative Team

The critical takeaway is that reactive hypoglycaemia is often a symptom that something else is out of balance, and whatever that is could contribute to your reactive hypoglycaemia, weight gain, and a myriad of other symptoms (i.e., see the symptom list above!)

The potential clinical use of antioxidants and antioxidant precursors in the treatment of COVID-19 needs to be seriously considered

However, people with a BMI of 27 or higher may also qualify if they have weight-related health conditions, such as type 2 diabetes or hypertension